Vantia

Vantia is an emerging pharmaceutical company developing novel small molecule drugs targeting large areas of unmet medical need. Its clinical pipeline includes fedovapagon (VA106483) for nocturia and VA111913 for dysmenorrhoea, product candidates that target conditions affecting millions of people, are poorly treated and represent billion dollar markets. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.